Combined modality therapy of Ewing's sarcoma

Area of Science:

• Oncology
• Pediatric Oncology
• Cancer Research

Background:

• Ewing's sarcoma is a rare bone cancer primarily affecting children and young adults.
• Effective treatment strategies are crucial for improving patient outcomes and survival rates.

Purpose of the Study:

• To evaluate the efficacy of combined local irradiation and adjuvant systemic chemotherapy in treating Ewing's sarcoma.
• To assess the impact of evolving chemotherapy regimens on patient survival and disease-free survival.

Main Methods:

• Retrospective analysis of 66 consecutive Ewing's sarcoma patients treated at the National Cancer Institute since 1964.
• Combination of local irradiation with progressively intensive adjuvant systemic chemotherapy regimens.
• Evaluation of actuarial survival rates (2-year and 5-year) and disease-free survival.

Main Results:

• Overall 2-year survival: 56%; 5-year survival: 35%.
• Patients without detectable metastases at diagnosis had 2-year survival: 64%; 5-year survival: 52%.
• Current protocol with alternating high-dose pulses of adriamycin and cyclophosphamide-vincristine shows improved disease-free survival.

Conclusions:

• Combined modality treatment including irradiation and intensive chemotherapy improves survival for Ewing's sarcoma.
• The current chemotherapy protocol demonstrates progress toward complete tumor eradication.
• Prognostic factors like metastatic disease, tumor site, age, and symptoms must be considered in future trial designs.